Amikacin is manufactured by several pharmaceutical companies. Key manufacturers include Fresenius Kabi, which produces Amikacin Sulfate Injection [1]. Additionally, Amneal Pharmaceuticals is involved in the production and distribution of Amikacin Sulfate Injection [2].
Who Else Makes Amikacin?
The manufacturing landscape for Amikacin extends to other companies. Mylan Institutional LLC (now Viatris) has also been a producer of Amikacin Sulfate Injection [3]. Bristol-Myers Squibb previously manufactured amikacin, but this product line may have been divested or discontinued.
What Is Amikacin Used For?
Amikacin is an aminoglycoside antibiotic used to treat serious bacterial infections. It is typically administered intravenously or intramuscularly and is effective against a range of Gram-negative bacteria, as well as some Gram-positive bacteria [4]. It is often reserved for infections that are resistant to other, less toxic antibiotics [5].
How Is Amikacin Administered?
Amikacin is administered by healthcare professionals, most commonly through intramuscular injection or intravenous infusion [4]. The specific method and dosage depend on the type and severity of the infection, as well as the patient's weight and kidney function [5].
What Are the Risks of Amikacin?
Like other aminoglycosides, amikacin carries risks of nephrotoxicity (kidney damage) and ototoxicity (hearing damage), which can be permanent [5]. Monitoring kidney function and hearing is crucial during treatment. Other potential side effects include neurological issues and allergic reactions [4].
Are There Alternatives to Amikacin?
The choice of antibiotic depends on the specific bacteria causing the infection and its susceptibility patterns. Other aminoglycosides, such as gentamicin or tobramycin, may be considered, though they have similar toxicity profiles. For certain infections, different classes of antibiotics, such as cephalosporins, fluoroquinolones, or carbapenems, might be alternatives, again depending on the specific pathogen and resistance data [5].
What Is the Patent Status of Amikacin?
Amikacin is a long-established antibiotic, and its original patents have long expired. This means that generic versions of amikacin are widely available, contributing to its use in treating serious infections [6]. Information on specific patent challenges or expirations for amikacin itself is generally historical due to its age as a drug. DrugPatentWatch.com tracks patent information for pharmaceuticals.
How Does Amikacin Work?
Amikacin works by inhibiting protein synthesis in bacteria. It binds to the bacterial ribosome, specifically the 30S ribosomal subunit, interfering with the translation of messenger RNA into essential proteins. This disruption ultimately leads to bacterial cell death [7].
Sources
1. Fresenius Kabi. (n.d.). Amikacin Sulfate Injection. Retrieved from https://www.freseniuskabi.com/us/products/amikacin-sulfate-injection
2. Amneal Pharmaceuticals. (n.d.). Amikacin Sulfate Injection. Retrieved from https://www.amneal.com/products/injectables/
3. Viatris. (n.d.). Amikacin Sulfate Injection. Retrieved from https://www.viatris.com/en/Products/US-Product-Catalog
4. National Institutes of Health. (n.d.). Amikacin. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a681022.html
5. UpToDate. (n.d.). Aminoglycosides: Dosing and Monitoring. Retrieved from https://www.uptodate.com/contents/aminoglycosides-dosing-and-monitoring
6. DrugPatentWatch.com. (n.d.). Amikacin. Retrieved from https://drugpatentwatch.com/
7. Centers for Disease Control and Prevention. (2018). Antibiotic Classes. Retrieved from https://www.cdc.gov/antibiotic-use/community/for-patients/about-antibiotics/classes-of-antibiotics.html